20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Hongchao Pan*, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I. Pritchard, Jonas Bergh, Mitch Dowsett, EBCTCG, Petrus Hupperets, Daniel F. Hayes

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1836-1846
Number of pages11
JournalNew England Journal of Medicine
Volume377
Issue number19
DOIs
Publication statusPublished - 9 Nov 2017

Keywords

  • SURGICAL ADJUVANT BREAST
  • LATE DISTANT RECURRENCE
  • CLINICAL-PRACTICE GUIDELINE
  • RANDOMIZED-TRIALS
  • POSTMENOPAUSAL WOMEN
  • TAMOXIFEN THERAPY
  • AMERICAN SOCIETY
  • SCORE
  • DISCONTINUATION
  • CHEMOTHERAPY

Cite this

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., EBCTCG, Hupperets, P., & Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 377(19), 1836-1846. https://doi.org/10.1056/NEJMoa1701830